The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $62.24 in the prior trading day, Vaxcyte Inc (NASDAQ: PCVX) closed at $62.43, up 0.31%. In other words, the price has increased by $0.31 from its previous closing price. On the day, 0.69 million shares were traded. PCVX stock price reached its highest trading level at $63.44 during the session, while it also had its lowest trading level at $61.775.
Ratios:
Our goal is to gain a better understanding of PCVX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.54 and its Current Ratio is at 7.54. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on December 07, 2023, initiated with a Buy rating and assigned the stock a target price of $69.
Needham reiterated its Buy rating for the stock on January 03, 2023, while the target price for the stock was revised from $52 to $58.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Wassil Jim sold 3,000 shares for $66.69 per share. The transaction valued at 200,066 led to the insider holds 218,289 shares of the business.
PICKERING GRANT sold 2,616 shares of PCVX for $174,502 on Apr 01 ’24. The CHIEF EXECUTIVE OFFICER now owns 147,362 shares after completing the transaction at $66.71 per share. On Apr 01 ’24, another insider, Eydelman Mikhail, who serves as the SVP, GEN COUNSEL & CORP SEC of the company, sold 1,667 shares for $66.73 each. As a result, the insider received 111,234 and left with 30,597 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCVX now has a Market Capitalization of 6789824512 and an Enterprise Value of 5716891648.
Stock Price History:
The Beta on a monthly basis for PCVX is 0.93, which has changed by 0.37541306 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, PCVX has reached a high of $82.04, while it has fallen to a 52-week low of $40.00. The 50-Day Moving Average of the stock is -11.15%, while the 200-Day Moving Average is calculated to be 9.33%.
Shares Statistics:
The stock has traded on average 843.44K shares per day over the past 3-months and 625710 shares per day over the last 10 days, according to various share statistics. A total of 108.41M shares are outstanding, with a floating share count of 102.89M. Insiders hold about 5.09% of the company’s shares, while institutions hold 91.66% stake in the company. Shares short for PCVX as of 1711584000 were 8260565 with a Short Ratio of 9.79, compared to 1709164800 on 8463285. Therefore, it implies a Short% of Shares Outstanding of 8260565 and a Short% of Float of 8.459999999999999.
Earnings Estimates
Vaxcyte Inc (PCVX) is currently under the scrutiny of 8 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$1.17 for the current quarter, with a high estimate of -$0.84 and a low estimate of -$1.72, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$1.15, with high estimates of -$0.9 and low estimates of -$1.74.
Analysts are recommending an EPS of between -$3.74 and -$4.75 for the fiscal current year, implying an average EPS of -$4.31. EPS for the following year is -$4.48, with 8 analysts recommending between -$3.02 and -$5.59.
